Stockreport

ORIC® Pharmaceuticals to Report Combination Dose Optimization Data From Phase 1b Trial of Rinzimetostat in Patients with mCRPC [Yahoo! Finance]

Oric Pharmaceuticals, Inc.  (ORIC) 
PDF SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, March 27, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on de [Read more]